Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

@article{Navari2007FosaprepitantA,
  title={Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting},
  author={Rudolph M Navari},
  journal={Expert Opinion on Investigational Drugs},
  year={2007},
  volume={16},
  pages={1977 - 1985}
}
  • R. Navari
  • Published 28 November 2007
  • Medicine
  • Expert Opinion on Investigational Drugs
Chemotherapy-induced nausea and vomiting (CINV) is a distressing and common adverse event associated with cancer treatment. Updated anti-emetic guidelines were published in 2007 by the National Comprehensive Cancer Network and in 2006 by the American Society of Clinical Oncology, which have included the use of the new and more effective anti-emetic agents (5-hydroxytryptamine-3 [5-HT3] receptor antagonists and neurokinin-1 [NK-1] receptor antagonists). Aprepitant is a selective NK-1 receptor… 
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
  • R. Navari
  • Medicine
    Drug design, development and therapy
  • 2015
TLDR
The clinical trials demonstrated that NEPA significantly improved the prevention of CINV compared to the use of palonosetron alone in patients receiving either HEC or MEC and the clinical efficacy was maintained over multiple cycles of chemotherapy.
Management of Chemotherapy-Induced Nausea and Vomiting
TLDR
Olanzapine, a US-FDA approved antipsychotic, has emerged in recent trials as an effective preventative agent for CINV, as well as a very effective agent for the treatment of breakthrough emesis and nausea.
Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis
TLDR
Taking into consideration the limitations of cross-trial comparisons, regimens containing neurokinin inhibitors are associated with higher CR rates than regimens not containing them and casopitant and aprepitant seem to be more effective than rolapitant regimens.
Efficacy and Safety of Neurokinin-1 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis of Randomized Controlled Trials.
TLDR
NK1-RAs improved the CR rate of CINV and might be associated with the appearance of diarrhea and hiccups, while decreasing the possibility of constipation and insomnia.
Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and
Chemotherapy-induced nausea and vomiting – standards in 2012
  • S. Lorenzen
  • Medicine
    memo - Magazine of European Medical Oncology
  • 2012
TLDR
This review provides an update of the revised clinical guidelines for antiemetic treatment and prophylaxis in cancer patients receiving chemotherapy.
Antiemetic control: toward a new standard of care for emetogenic chemotherapy
TLDR
Future studies may consider the use of palonosetron, aprepitant and casopitant with other antiemetic agents (olanzapine, gabapentin, cannabinoids) in moderately and highly emetogenic chemotherapy, as well as in the clinical settings of multiple-day chemotherapy and bone marrow transplantation.
The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting
  • R. Navari
  • Medicine
    Expert opinion on drug safety
  • 2016
TLDR
Olanzapine, an antipsychotic that blocks multiple neurotransmitters in the central nervous system, appears to be effective in the prevention of nausea and emesis with mild short term sedation the only reported adverse event.
New therapies for antiemetic prophylaxis for chemotherapy.
  • Mellar P. Davis
  • Medicine
    The Journal of community and supportive oncology
  • 2016
TLDR
Rolapitant, another NK1RA, has a long half-life and does not block CYP-3A4 and therefore has fewer drug interactions and is a better rescue antiemetic than is metoclopramide.
Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
  • I. Olver
  • Medicine
    Therapeutics and clinical risk management
  • 2008
TLDR
Fosaprepitant can be used as a parenteral alternative to aprepitant in regimens to control chemotherapy-induced emesis and improves the control of acute post chemotherapy emesis when added to dexamethasone and a 5HT3 receptor antagonist.
...
1
2
3
4
...

References

SHOWING 1-10 OF 58 REFERENCES
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
TLDR
The neurokinin-1-receptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin and combined with granisetron plus dexamethasone improves the prevention of acute emesis.
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
TLDR
A single dose of L-758,298 substantially suppressed the delayed nausea and vomiting characteristic of high dose cisplatin and also appeared to reduce acute emesis post-cisplatin, supporting the proposition that the underlying mechanism(s) of acute and delayed emesis are different.
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
  • P. Hesketh, S. Grunberg, +11 authors K. Horgan
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Compared with standard dual therapy, addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients receiving highly emetogenic cisplatin-based chemotherapy.
Emerging drugs for chemotherapy-induced emesis
TLDR
Future studies may consider the use of palonosetron and aprepitant with current and other new agents (olanzapine, gabapentin) in moderately and highly emetogenic chemotherapy, as well as in the clinical settings of multiple-day chemotherapy and bone marrow transplantation.
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
  • D. Campos, J. R. Pereira, +9 authors B. Gertz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
Once daily oral administration of MK-869 was effective in reducing delayed emesis and nausea after high-dose cisplatin, however, the combination of the 5HT3 antagonist plus dexamethasone was numerically superior to MK- 869 plus DexamethAsone in reducing acute emesis.
The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
TLDR
Data show that MK-0869 and its prodrug, L-758,298, have good activity against cisplatin-induced emesis in ferrets and provided a basis for the clinical testing of these agents for the treatment of emesis associated with cancer chemotherapy.
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
TLDR
Combined data from the multiple cycles extensions of two phase III clinical trials of oral aprepitant plus standard therapy for the prevention of chemotherapy-induced nausea and vomiting found antiemetic protection that was well maintained over multiple cycles of highly emetogenic chemotherapy.
Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
TLDR
The authors sought to evaluate further the efficacy and tolerability of aprepitant plus standard therapy in a large clinical trial.
...
1
2
3
4
5
...